Intimation under Regulations 30 and 51 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations') and Securities and Exchange Board of India's circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015 Intimation under Regulations 30 and 51 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended - Certified copy of order passed by by Hon'ble National Company Law Tribunal, Mumbai Bench sanctioning the Scheme as below (As Per BSE Announcement Dated on 16.08.2022) Trading Members of the Exchange are hereby informed that, pursuant to the Composite Scheme of Arrangement (for Demerger) between Piramal Enterprises Ltd (Demerged Company) and Piramal Pharma Ltd (Resulting Company) and 3 others and their respective shareholders and creditors approved by the Hon'ble National Company Law Tribunal, Mumbai Bench (NCLT), Piramal Enterprises Limited has fixed Record Date for the purpose of determining entitlement of the shareholders of the Company, as per details given below: - COMPANY NAME CODE Piramal Enterprises Limited (500302) RECORD DATE 01/09/2022 PURPOSE As per Composite Scheme of Arrangement (Demerger) sanctioned by the Hon'ble National Company Law Tribunal, Mumbai Bench (NCLT), between, Piramal Enterprises Limited (Demerged Company) and Piramal Pharma Limited (Resulting Company) and Their Respective Shareholders and Creditors: - Upon the coming into effect of the aforesaid Scheme and in consideration of the transfer and vesting of Pharma Business Undertaking of Piramal Enterprises Limited into Piramal Pharma Limited ; Piramal Pharma Limited shall issue and allot Equity Shares to the shareholders of Piramal Enterprises Limited in the following proportion: '4 fully paid up equity shares of Rs.10/- each fully paid up of Piramal Pharma Limited shall be issued and alloted For every 1 fully paid up equity shares of Rs. 2/- each fully paid up held in Piramal Enterprises Limited' EX-ENTITLEMENT FROM DATE & SETT. NO. 30/08/2022 DR-105/2022-2023 Note: Pursuant to SEBI Circular No. CIR/MRD/DP/01/2012 dated January 20, 2012; the aforesaid scrip shall be a part of Call Auction in Pre-open Session on August 03, 2022. Subject to compliance with requisite formalities, the shares of Resulting companies i.e. Piramal Pharma Limited will be listed on BSE Limited. (As Per BSE Notice Dated on 25.08.2022) Intimation under Regulations 30 and 51 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended - Sanction of Scheme by Hon'ble National Company Law Tribunal, Mumbai Bench (As per BSE Announcement Dated on 12/08/2022) Intimation of Record Date under Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (As Per BSE Announcement Dated on 18.08.2022) Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (''SEBI Listing Regulations'') (As per BSE Announcement Dated on 27/01/2025)